Can GLP-1s Treat Cancer? Ozempic and Cancer Risk Explained

Key Points:

• Early observational studies suggest that GLP-1 receptor agonists may reduce the risk of several obesity-related cancers, including breast, colorectal, and liver cancer, by addressing metabolic factors such as inflammation, insulin levels, and weight management.
• GLP-1 medications promote healthy weight loss, reduce chronic inflammation, lower postmenopausal estrogen levels, and improve insulin sensitivity, which collectively may contribute to lowering cancer risk.
• Despite promising findings, GLP-1 drugs are not FDA-approved for cancer prevention, and experts stress the need for prospective clinical trials to establish causation and regulatory approval.
• The main cancer-related safety concern involves a rare risk of medullary thyroid carcinoma, based on animal studies, leading to warnings against use in patients with a history of this cancer or related syndromes.
• Patients concerned about cancer risk should continue following established screening guidelines and discuss metabolic health factors with their healthcare providers, while researchers continue to explore the potential role of GLP-1s in oncology.